



The Innovative Medicines Initiative (IMI)



History, Concept and Organisation



Irene Norstedt



History



2000

Lisbon Strategy Europe most competitive and dynamic knowledge-based economy by 2010

2004

European Technology Platforms

stakeholders under the lead of industry develops Strategic Research Agendas addressing bottlenecks to competitiveness

2007

7th Framework Programme for Research

Major novelties: European Research Council and Joint Technology Initiatives

2008

Establishment of the Joint Undertakings to implement the Joint Technology Initiatives





Joint Technology Initiatives



Long term public-private partnerships in research at European level

Coordinated research efforts responding to industry needs

Focus on fields of high industrial and policy relevance

Building on European Technology Platforms

To be implemented through new legal entities - Joint Undertakings


20 December 2007 Council Decision to establish four Joint Undertakings: IMI, Clean Sky, ARTEMIS, ENIAC



**COUNCIL REGULATION (EC) No 73/2008
of 20 December 2007**

**setting up the Joint Undertaking for the
implementation of the Joint Technology
Initiative on
Innovative Medicines**

Official Journal 04.02.2008





- IMI aims at removing major bottlenecks in drug development, where **research** is the key
- With the long term goal to re-invigorate the European bio-pharmaceutical sector and foster Europe as the most attractive place for pharmaceutical R&D, thereby, in the long term, enhancing access to innovative medicines for patients.
- IMI will support 'pre-competitive pharmaceutical research and development', in order to accelerate the development of safer and more effective medicines for patients.
- No new medicines will be developed as such as the focus shall be on the delivery of new approaches, methods and technologies, improve knowledge management of research results and data, and support the training of professionals.



- IMI will support research activities following open and competitive calls for project proposals, peer review evaluation and the conclusion of Grant Agreements and Project Agreements.
- The research will be funded by a combination of a financial contribution from the IMI JU to academia, SMEs, patients associations, etc. and a contribution 'in kind' from the participating EFPIA member companies.
- The call and evaluation process is tailor made to serve the objectives of IMI
- The IMI IP policy is aligned with the objectives of IMI - findings (Foreground) must be widely and readily available for research into the discovery and development of medicines
- The IMI IP policy provides incentives for all actors to participate (i.e. the ownership interest, direct exploitation and the fair return on investment must be preserved)




- IMI shall foster collaboration between all stakeholders, e.g. industry, public authorities (including regulators), organisations of patients, academia and clinical centres.
- IMI will launch one call for proposals 2008 – today!!!
- Topics included in the first call are based on IMI's Scientific Priorities for 2008 and are derived from the IMI Research Agenda.
- Areas in the IMI Research Agenda not addressed in 2008 will be addressed in consecutive calls.



IMI Governance




IMI JTI = IMI JU + External Advisory Groups





IMI Joint Undertaking



2 Founding Members



Overall responsibility for the operations of IMI

Responsible for day-to-day management

15 members

Scientific Advise to the Board





IMI External Advisory Bodies



Annual meeting open to all stakeholders

Communication


Stakeholder Forum

One representative per Member and Associated State

Interface with stakeholders in MS/AS and communication

Chair observer in Governing Board

IMI States Representatives Group





State of Play



- Council Regulation entered into force 7 February 2008
- Governing Board meetings 3 March and 29 April 2008
- Interim Executive Director has been appointed
- Process for setting up the Scientific Committee has started by inviting proposal for candidates from the Member and Associated States
- Process for setting up the IMI States Representatives Group has started by inviting Member and Associated States to nominate representatives



State of Play

Starting the operations



- Launching the first call for proposals 30 April 2008
- Start recruitment Executive Director and key staff
- Set up office in Brussels



Expected outcomes



- Modernisation of the development process of medicines
- More and better quality jobs for scientists, reversing the brain drain
- Better European Expertise and know how in technologies to attract biomedical R&D investment to Europe
- Stronger competitive advantage for smaller companies (SMEs, spin-offs and start ups) by collaboration with a multitude of stakeholders to enhance Europe's competitiveness.



Thank you for your attention